Archive
Chemotherapy neoadjuvant chemotherapy increases breast conservation in the tumor operable: the Egyptian experience
No Abdel-Bary, r. f. El-Kased, h. A.Z. Aiad
Introduction: the role of adjuvant chemotherapy in breast cancer is well established as have the signs.Similarly, the role of neoadjuvant chemotherapy in cancer chemotherapy in locally advanced is well-defined. the use of neoadjuvant chemotherapy in cancer chemotherapy operable only recently has become of interest for researchers.
Patients and methods: this study included 34 cases of tumor operable who were given 4 rounds of chemotherapy of neoadjuvant chemotherapy in form of FEC100 then undergoing surgery.In fact had Surgery or breast conserving surgery (BCS) or modified radical mastectomy. all patients completed the treatment regimen and not patients were excluded from the study. All surgical specimens were studied pathologically effect of chemotherapy.
Results: A general objective response was observed in 70.6% of patients. Seven patients (20.6%) experienced a complete clinical response (JRC), seventeen patients (50,0%) had partial answer, nine patients (26.5%) had no change in their disease and one patient had disease progression.Of the seven patients who had a RAC, only four patients (11.8%) had the pathological complete response (pCR), while the pCR for the entire group was14.7% (5/34). tumor size of more than 2 cm has been reported in 28patients (82.4%) at the time, while the tumour size of 2 cm or less was seen in 6 patients (17.6%) only.After completing the course of chemotherapy, twenty three patients (67.6%) were observed tumours 2 cm or may not have that allowed for less extended resections.Twenty three patients have suffered conservative breast surgery (67.6%) while editing for the radical mastectomy has been performed in 11 patients (32.4%).
Conclusion:: the use of neoadjuvant chemotherapy in cancer chemotherapy operable in this study was associated with tumor and axillary downstaging which increased the percentage of cases being breast conservation with reasonable cost, and acceptable effects. During follow-up limited time of this study were observed not loco regional anniversaries and registered a distant treatment error. the impact, if any, on overall survival or disease-free status is still in progress.
Volume: 3 article number: 104 DOI: 10.3332/ecancer. 2008 104 received: 07/11/2008 published: 09/04/2009
To view this article in its entirety, you must first sign in or register.
Support regimen of chemotherapy intensified ChlVPP/ABVVP and pegfilgrastim in advanced Hodgkin’s lymphoma
E. Vanazzi Cocorocchio, a., s. Bassi, f. Sinners, p. Antoniotti, f. Gigli, l. Travaini, g. Piperno, g. Pruneri, l. Prey, r. Biffi, Botteri e., Negri m. and g. Martinelli
We present the feasibility, toxicity and efficacy results of intensified 6 cycles ChlVPP/ABVVP regimen in advanced Hodgkin’s Lymphoma (HL). From February 2004 to August 2007, 82 patients were enrolled eligible consecutively. Second Hasenclever index 64 patients (78%) were considered low risk, 15 (6%) to intermediate and 3 (4%) high risk. The most important was hematologic toxicity: grade 3-4 neutropenia occurred in 34% of patients, a grade 3-4 anemia in 28% of patients. In 8% of patients were observed severe infections and febrile neutropenia.With a median follow-up of 35 months (range 12-55), freedom of three years from the treatment failure (FFTF) and overall survival (OS) were 75% (95% CI: 65-86%) and 94% (95% CI: 87-99%), respectively. Intensified regimen ChlVPP/advanced ABVVP in HL is effective, does not seem to differ from standard regimens in terms of FFTF and OS and showed a favourable toxicity profile.
Volume: 4 article number: 184 DOI: 10.3332/ecancer. 2010.184 received: 23/04/2010 published: 08/09/2010
To view this article in its entirety, you must first sign in or register.
Long QT syndrome and torsade de he exhibited after chemotherapy anthracycline derivative
N. Columbus m. Craig, Cardinal d., g. Lamantia, r. Colombo, g. De Giacomi, c. Onion
Unfortunately, anthracycline chemotherapy, which is the treatment of choice for many types of hematological and metastatic breast cancer brings with it the possibility of two early cardiotoxic phenomena, which occur during chemotherapy and Furthermore, late cardiotoxic events occurring even months or years after completion of treatment.
The clinical manifestations of the early cardiotoxicity commonly include: ventricular premature beats, supraventricular, cardiomyopathy and sudden death.
This study confirms the need for careful monitoring cardiac patients undergoing therapy anthracycline derivative. such monitoring should not only include the echocardiographic monitoring for diastolic dysfunction systo-left ventricular but also elettrocardiografici monitoring (QTc) in order to exclude electrophysiological changes possible link to life threatening arrhythmias (10).
Volume: 3 article number: 147 DOI: 10.3332/ecancer. 2009 147 received: 01/04/2009 published: 08/06/2009
To view this article in its entirety, you must first sign in or register.
The impact of a dose rate reduction adjuvant chemotherapy anthracycline derivative based on a population-based cohort of breast cancers of phase I and II
A. Tinker, c. Speers, j. Barnett, r. i. Olivotto, s. chia
Background: reduction of dose rate (DI) of adjuvant chemotherapy anthracycline derivative based early tumor stage are often required due to toxicity treatment or poor tolerance, but the implications of a minimal reduction OF clinical outcome remains uncertain.
Patients and methods: women with stage I-ii cancer treated with ADRIAMYCIN and cyclophosphamide adjuvant (AC) from 1990-1995 were identified in a database of provincial breast cancer. Cases were classified into 4 cohorts 1: all cycles and brought to full dose in time 2: a single dose or dose reduction delay 3: > 1 dose or dose reduction delay: 4
Results: 484 eligible cases have been identified (cohort 1: n = 268 2: n = 88 3: n = 89 4: n = 39).Slight imbalances in lymph node status (p = 0,05) and adjuvant hormonal therapy (p = 0,05) were observed among cohorts.(267/484) 55% of patients had node-positive disease and 33% (158/484) were ER +. 45% of the cases had a reduction OF. With a median follow-up of 9.6 years, there were significant differences in relapse-free survival (p = 0.94), cancer-specific survival of breast (p = 0.87) or overall survival (p = 0.86) among cohorts 4. the results were independent hormone receptor status.
Conclusions: although related the toxicity OF chemotherapy adjuvant AC reductions for early stage breast cancer are common, they do not seem significant impact on clinical outcomes in this population-based cohort of women with stage I and II.
Volume: 2 article number: 63 DOI: 10.3332/eCMS. 2008.63 received: 07/12/2007 published: 07/08/2008
To view this article in its entirety, you must first sign in or register.
cancer3 